



Scandinavian Sarcoma Group Studies and Activities Ongoing or In Development

Sigbjørn Smeland




SSG osteosarcoma studies

Ongoing			
EUROBOSS	> 41	Phase II	(2012)
EURAMOS-1	≤ 40	Randomised Phase III	(2010/11)
SSG registry	All patients	From 1986	(survivorship!)
LSYAA project	Study patients ≤ 40		
Planned			
Haplo-Tx	Hard to treat osteosarcoma		
Alpharadin	Hard to treat osteosarcoma		



Bone-Seeking Alpha Radiotherapy: $^{223}\text{RaCl}_2$ (Alpharadin) for Osteosarcoma

Axial primary tumors



Bone-forming metastases






Table 1. Decay and Marrow/Bone Ratios Clinically Useful Bone-seeking Isotopes

	Half-life	*Ratio of Surface Days	<u>Bone : red marrow</u>	<u>Particle</u>	MeV particle <u>Emission energy</u>	Range <u>(mm)</u>
¹⁵³ Sm-EDTMP	2	4.4		Beta	0.66 max 0.22 average	0.6
⁸⁹ SrCl ₂	50.5	1.6		Beta	0.58	2.4
²²³ RaCl	11.4	10.3		Alpha	27.4	<0.1

* Bone surface to red bone marrow radioactivity dose ratio